Search

Displaying results 7351 - 7360 of 10000 in total
  1. Drug

    Caviar, unspecified

    go.drugbank.com/drugs/DB14241
    Approved

    Caviar, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

    Synonyms: 8 AG
  3. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

  4. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as

  5. Drug

    Paquinimod

    go.drugbank.com/drugs/DB13118
    Investigational

    Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. … The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

  6. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

  7. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence Phase 1 clinical trials of this vaccine (NCT04449276).

  8. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.

  9. Drug

    Cetrelimab

    go.drugbank.com/drugs/DB15421
    Investigational

    Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD … )-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).

  10. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    Bisegliptin is a compound for the treatment of type 2 diabetes. … It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion